Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$40.71 USD
-1.05 (-2.51%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $40.73 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$40.71 USD
-1.05 (-2.51%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $40.73 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -12.25% and 91.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of -2.38% and 15.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of 10.11% and 11.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 7.89% and 4.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 38.46% and 0.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of -16.16% and 19.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -21.28% and 11.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Tabula Rasa Healthcare (TRHC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of -28.57% and 0.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -39.44% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 18.18% and 4.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Xenon Pharmaceuticals (XENE) Q3 Earnings Expected to Decline
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Xenon (XENE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Xenon (XENE) stock based on the movements in the options market lately.
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -4.08% and -13.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 15.00% and 47.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -66.67% and -36.54%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Reports Break-Even Earnings for Q2
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 100.00% and 102.79%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
ACADIA to Merge Two Phase III Studies on Nuplazid for MDD
by Zacks.com
ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.
Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 29.03% and -5.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan
by Zacks Equity Research
The U.S. Patent and Trademark Office imparts a ruling in favor of Biogen (BIIB) over generic drugmaker Mylan to protect the patent of its best-selling multiple sclerosis drug, Tecfidera.
What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?
by Zacks Equity Research
Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.
Top Ranked Momentum Stocks to Buy for February 4th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 4th
Aimmune's Palforzia Wins FDA Approval for Peanut Allergy
by Zacks Equity Research
Aimmune's (AIMT) Palforzia is the first medicine to receive an FDA nod for treating patients with peanut allergy. Shares rise in pre-market trading.
Top Ranked Momentum Stocks to Buy for January 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 24th
Are You Looking for a Top Momentum Pick? Why Xenon Pharmaceuticals (XENE) is a Great Choice
by Zacks Equity Research
Does Xenon Pharmaceuticals (XENE) have what it takes to be a top stock pick for momentum investors? Let's find out.